Multiple sclerosis

High-efficacy therapies reduce relapses in patients with active SPMS

The more potent disease-modifying drugs in multiple sclerosis are superior to low-efficacy therapy in reducing relapses in patients with active but not inactive secondary progressive multiple sclerosis (SPMS), Australian research shows. A study led by neurologists Dr Izanne Roos and Professor Tomas Kalincik,  of the Clinical Outcomes Research (CORe) Unit, Melbourne University, investigated relapse rates ...

Already a member?

Login to keep reading.

© 2021 the limbic